Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Packer

Showing results (51-60 of 326) with videos related to

Pageof 33
Sort By:
Journal of the American College of Cardiology|November 1, 1996
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?M Packer
The American Journal of Cardiology|January 3, 1989
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failureM Packer
Circulation|January 1, 1989
Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?M Packer
The New England Journal of Medicine|March 16, 1989
Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectorisM Packer
Journal of the American College of Cardiology|February 1, 1987
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind menM Packer
Chest|June 1, 1989
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?M Packer
The Western Journal of Medicine|July 1, 1990
Due processM Packer
Cardiology|January 1, 1989
Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failureM Packer
Circulation|December 1, 1989
Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failureM Packer
Annals of Internal Medicine|August 1, 1985
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazardsM Packer
Pageof 33

Showing results (51-60 of 326) with videos related to

Sort By:
Pageof 33
Journal of the American College of Cardiology|November 1, 1996
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?M Packer
The American Journal of Cardiology|January 3, 1989
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failureM Packer
Circulation|January 1, 1989
Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?M Packer
The New England Journal of Medicine|March 16, 1989
Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectorisM Packer
Journal of the American College of Cardiology|February 1, 1987
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind menM Packer
Chest|June 1, 1989
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?M Packer
The Western Journal of Medicine|July 1, 1990
Due processM Packer
Cardiology|January 1, 1989
Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failureM Packer
Circulation|December 1, 1989
Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failureM Packer
Annals of Internal Medicine|August 1, 1985
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazardsM Packer
Pageof 33